Assessing and treating small airways disease in asthma and chronic obstructive pulmonary disease

Annals of Medicine

Volumn 44, Issue 2, 2012, Pages 146-156

  Usmani, Omar S ^a,b   Barnes, Peter J ^a,b  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

Asthma; chronic obstructive pulmonary disease; drug particle size; physiology; Small airways; therapy

Indexed keywords

ANTIINFLAMMATORY AGENT; BECLOMETASONE DIPROPIONATE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CICLESONIDE; CORTICOSTEROID; FLUNISOLIDE; FORMOTEROL; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MUSCARINIC RECEPTOR BLOCKING AGENT; TIOTROPIUM BROMIDE;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ASSESSMENT; COMPUTER ASSISTED TOMOGRAPHY; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG MEGADOSE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; IMMUNOPATHOLOGY; INHALATIONAL DRUG ADMINISTRATION; LUNG FUNCTION TEST; LUNG SCINTISCANNING; MEDICAL TECHNOLOGY; MORPHOLOGY; NITROGEN WASHOUT; OCCUPATIONAL ASTHMA; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SMALL AIRWAY DISEASE;

AEROSOLS; AIRWAY REMODELING; AIRWAY RESISTANCE; ASTHMA; FEMALE; HUMANS; MALE; NEBULIZERS AND VAPORIZERS; PARTICLE SIZE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY FUNCTION TESTS; RESPIRATORY SYSTEM;

EID: 84857722564     PISSN: 07853890     EISSN: 13652060     Source Type: Journal    
DOI: 10.3109/07853890.2011.585656     Document Type: Article

References (111)

1. Weibel ER. Morphometry of the human lung. Berlin: Springer-Verlag; 1963.
2. Baraldo S, Saetta M, Cosio MG. Pathophysiology of the small airways. Semin Respir Crit Care Med. 2003;24:465-72.
3. Macklem PT, Mead J. Resistance of central and peripheral airways measured by a retrograde catheter. J Appl Physiol. 1967;22:395-401.
4. Mead J. The lung' s 'q uiet zone' . N Engl J Med. 1970; 282:1318-9.
5. Barnes PJ. Against the Dutch hypothesis: asthma and chronic obstructive pulmonary disease are distinct diseases. Am J Respir Crit Care Med. 2006;174:240-3.
6. Hamid Q, Song Y, Kotsimbos TC, Minshall E, Bai TR, Hegele RG, et al. Infl ammation of small airways in asthma. J Allergy Clin Immunol. 1997;100:44-51.
7. Hogg JC, Chu F, Utokaparch S, Woods R, Elliott WM, Buzatu L, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med. 2004;350:2645-53.
8. Contoli M, Bousquet J, Fabbri LM, Magnussen H, Rabe KF, Siafakas NM, et al. The small airways and distal lung compartment in asthma and COPD: a time for reappraisal. Allergy. 2010;65:141-51.
9. Gelfand EW, Kraft M. The importance and features of the distal airways in children and adults. J Allergy Clin Immunol. 2009;124:S84-7.
10. Saetta M, Di Stefano A, Rosina C, Thiene G, Fabbri LM. Quantitative structural analysis of peripheral airways and arteries in sudden fatal asthma. Am Rev Respir Dis. 1991;143:138-43.
11. Dolhnikoff M, da Silva LF, de Araujo BB, Gomes HA, Fernezlian S, Mulder A, et al. The outer wall of small airways is a major site of remodeling in fatal asthma. J Allergy Clin Immunol. 2009;123:1090-7.
12. Shiang C, Mauad T, Senhorini A, de Ara újo BB, Ferreira DS, da Silva LF, et al. Pulmonary periarterial infl ammation in fatal asthma. Clin Exp Allergy. 2009;39:1499-507.
13. Mauad T, Silva LF, Santos MA, Grinberg L, Bernardi FD, Martins MA, et al. Abnormal alveolar attachments with decreased elastic fi ber content in distal lung in fatal asthma. Am J Respir Crit Care Med. 2004;170:857-62.
14. Saetta M, Ghezzo H, Kim WD, King M, Angus GE, Wang NS, et al. Loss of alveolar attachments in smokers. A morphometric correlate of lung function impairment. Am Rev Respir Dis. 1985;132:894-900.
15. Lams BE, Sousa AR, Rees PJ, Lee TH. Subepithelial immunopathology of the large airways in smokers with and without chronic obstructive pulmonary disease. Eur Respir J. 2000;15:512-6.
16. Battaglia S, Mauad T, van Schadewijk AM, Vignola AM, Rabe KF, Bellia V, et al. Differential distribution of infl ammatory cells in large and small airways in smokers. J Clin Pathol. 2007;60:907-11.
17. Haley KJ, Sunday ME, Wiggs BR, Kozakewich HP, Reilly JJ, Mentzer SJ, et al. Infl ammatory cell distribution within and along asthmatic airways. Am J Respir Crit Care Med. 1998; 158:565-72.
18. Carroll N, Cooke C, James A. The distribution of eosinophils and lymphocytes in the large and small airways of asthmatics. Eur Respir J. 1997;10:292-300.
19. Saetta M, Di Stefano A, Turato G, Facchini FM, Corbino L, Mapp CE, et al. CD8lymphocytes in peripheral airways of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;157:822-6.
20. Saetta M, Mariani M, Panina-Bordignon P, Turato G, Buonsanti C, Baraldo S, et al. Increased expression of the chemokine receptor CXCR3 and its ligand CXCL10 in peripheral airways of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2002;165:1404-9.
21. King GG, Salome CM. Multimodality measurements of small airways disease. Eur Respir J. 2006;27:250-2.
22. Kraft M, Djukanovic R, Wilson S, Holgate ST, Martin RJ. Alveolar tissue infl ammation in asthma. Am J Respir Crit Care Med. 1996;154:1505-10.
23. Balzar S, Wenzel SE, Chu HW. Transbronchial biopsy as a tool to evaluate small airways in asthma. Eur Respir J. 2002;20:254-9.
24. Marshall BG, Wangoo A, Harrison LI, Young DB, Shaw RJ. Tumour necrosis factor-alpha production in human alveolar macrophages: modulation by inhaled corticosteroid. Eur Respir J. 2000;15:764-70.
25. Hargreave FE. Induced sputum for the investigation of airway infl ammation: evidence for its clinical application. Can Respir J. 1999;6:169-74.
26. Ueda T, Niimi A, Matsumoto H, Takemura M, Hirai T, Yamaguchi M, et al. Role of small airways in asthma: investigation using high-resolution computed tomography. J Allergy Clin Immunol. 2006;118:1019-25.
27. Abbott GF, Rosado-de-Christenson ML, Rossi SE, Suster S. Imaging of small airways disease. J Thorac Imaging. 2009; 24:285-98.
28. Tashkin DP, de Lange EE. Imaging of the distal airways. J Allergy Clin Immunol. 2009;124:S78-83.
29. Samee S, Altes T, Powers P, de Lange EE, Knight-Scott J, Rakes G, et al. Imaging the lungs in asthmatic patients by using hyperpolarized helium-3 magnetic resonance: assessment of response to methacholine and exercise challenge. J Allergy Clin Immunol. 2003;111:1205-11.
30. de Lange EE, Altes TA, Patrie JT, Gaare JD, Knake JJ, Mugler JP 3rd, et al. Evaluation of asthma with hyperpolarized helium-3 MRI: correlation with clinical severity and spirometry. Chest. 2006;130:1055-62.
31. van Beek EJ, Dahmen AM, Stavngaard T, Gast KK, Heussel CP, Krummenauer F, et al. Hyperpolarised 3He MRI versus HRCT in COPD and normal volunteers: PHIL trial. Eur Respir J. 2009;34:1311-21.
32. Jang YM, Oh YM, Seo JB, Kim N, Chae EJ, Lee YK, et al. Quantitatively assessed dynamic contrast-enhanced magnetic resonance imaging in patients with chronic obstructive pulmonary disease: correlation of perfusion parameters with pulmonary function test and quantitative computed tomography. Invest Radiol. 2008;43:403-10.
33. Musch G, Venegas JG. Positron emission tomography imaging of regional pulmonary perfusion and ventilation. Proc Am Thorac Soc. 2005;2:522-7.
34. De Backer JW, Vos WG, Vinchurkar SC, Claes R, Drollmann A, Wulfrank D, et al. Validation of computational fl uid dynamics in CT-based airway models with SPECT/CT. Radiology. 2010;257:854-62.
35. Goldin JG. Imaging the lungs in patients with pulmonary emphysema. J Thorac Imaging. 2009;24:163-70.
36. Awadh N, Mü ller NL, Park CS, Abboud RT, FitzGerald JM. Airway wall thickness in patients with near fatal asthma and control groups: assessment with high resolution computed tomographic scanning. Thorax. 1998;53:248-53.
37. Park CS, Mü ller NL, Worthy SA, Kim JS, Awadh N, Fitzgerald M. Airway obstruction in asthmatic and healthy individuals: inspiratory and expiratory thin-section CT fi ndings. Radiology. 1997;203:361-7.
38. Mitsunobu F, Ashida K, Hosaki Y, Tsugeno H, Okamoto M, Nishida N, et al. Decreased computed tomographic lung density during exacerbation of asthma. Eur Respir J. 2003; 22:106-12.
39. Akira M, Toyokawa K, Inoue Y, Arai T. Quantitative CT in chronic obstructive pulmonary disease: inspiratory and expiratory assessment. Am J Roentgenol. 2009;192:267-72.
40. Laurent F, Latrabe V, Raherison C, Marthan R, Tunonde-Lara JM. Functional signifi cance of air trapping detected in moderate asthma. Eur Radiol. 2000;10:1404-10.
41. Matsuoka S, Kurihara Y, Yagihashi K, Hoshino M, Watanabe N, Nakajima Y. Quantitative assessment of air trapping in chronic obstructive pulmonary disease using inspiratory and expiratory volumetric MDCT. AJR Am J Roentgenol. 2008;190:762-9.
42. Goldin JG, Tashkin DP, Kleerup EC, Greaser LE, Haywood UM, Sayre JW, et al. Comparative effects of hydrofl uoroalkane and chlorofl uorocarbon beclomethasone dipropionate inhalation on small airways: assessment with functional helical thin-section computed tomography. J Allergy Clin Immunol. 1999;104:S258-67.
43. Tunon-de-Lara JM, Laurent F, Giraud V, Perez T, Aguilaniu B, Meziane H, et al. Air trapping in mild and moderate asthma: effect of inhaled corticosteroids. J Allergy Clin Immunol. 2007;119:583-90.
44. van Beek EJ, Wild JM. Hyperpolarized 3-helium magnetic resonance imaging to probe lung function. Proc Am Thorac Soc. 2005;2:528-32.
45. Peces-Barba G, Ruiz-Cabello J, Cremillieux Y, Rodríguez I, Dupuich D, Callot V, et al. Helium-3 MRI diffusion coeffi-cient: correlation to morphometry in a model of mild emphysema. Eur Respir J. 2003;22:14-19.
46. Woods JC, Choong CK, Yablonskiy DA, Bentley J, Wong J, Pierce JA, et al. Hyperpolarized 3He diffusion MRI and histology in pulmonary emphysema. Magn Reson Med. 2006; 56:1293-300.
47. Fain SB, Panth SR, Evans MD, Wentland AL, Holmes JH, Korosec FR, et al. Early emphysematous changes in asymptomatic smokers: detection with 3He MR imaging. Radiology. 2006;239:875-83.
48. Wang C, Altes TA, Mugler JP 3rd, Miller GW, Ruppert K, Mata JF, et al. Assessment of the lung microstructure in patients with asthma using hyperpolarized 3He diffusion MRI at two time scales: comparison with healthy subjects and patients with COPD. J Magn Reson Imaging. 2008; 28:80-8.
49. Pride NB. Tests of forced expiration and inspiration. Clin Chest Med. 2001;22:599-622.
50. Scichilone N, Battaglia S, Olivieri D, Bellia V. The role of small airways in monitoring the response to asthma treatment: what is beyond FEV1? Allergy. 2009;64:1563-9.
51. Lung function testing: selection of reference values and interpretive strategies. American Thoracic Society. Am Rev Respir Dis. 1991;144:1202-18.
52. Hansen JE, Sun XG, Wasserman K. Discriminating measures and normal values for expiratory obstruction. Chest. 2006;129:369-77.
53. Stocks J, Quanjer PH. Reference values for residual volume, functional residual capacity and total lung capacity. Eur Respir J. 1995;8:492-506.
54. O' D onnell DE, Laveneziana P. The clinical importance of dynamic lung hyperinfl ation in COPD. COPD. 2006;3: 219-32.
55. Lougheed MD, Fisher T,O'Donnell DE. Dynamic hyperinfl ation during bronchoconstriction in asthma: implications for symptom perception. Chest. 2006;130:1072-81.
56. Mahut B, Bokov P, Delclaux C. Abnormalities of plethysmographic lung volumes in asthmatic children. Respir Med. 2010;104:966-71.
57. Sorkness RL, Bleecker ER, Busse WW, Calhoun WJ, Castro M, Chung KF, et al. National Heart, Lung, and Blood Institute Severe Asthma Research Program. Lung function in adults with stable but severe asthma: air trapping and incomplete reversal of obstruction with bronchodilation. J Appl Physiol. 2008;104:394-403.
58. Drummond GB, Milic-Emili J. Forty years of closing volume. Br J Anaesth. 2007;99:772-4.
59. Veen JC, Beekman AJ, Bel EH, Sterk PJ. Recurrent exacerbations in severe asthma are associated with enhanced airway closure during stable episodes. Am J Respir Crit Care Med. 2000;161:1902-6.
60. Bourdin A, Paganin F, Pr éfaut C, Kieseler D, Godard P, Chanez P. Nitrogen washout slope in poorly controlled asthma. Allergy. 2006;61:85-9.
61. O'Donnell DE, Laveneziana P, Ora J, Webb KA, Lam YM, Ofir D. Evaluation of acute bronchodilator reversibility in patients with symptoms of GOLD stage I COPD. Thorax. 2009;64:216-23.
62. Woolcock AJ, Vincent NJ, Macklem PT. Frequency dependence of compliance as a test for obstruction in the small airways. J Clin Invest. 1969;48:1097-106.
63. Evans DJ, Green M. Small airways: a time to revisit? Thorax. 1998;53:629-30.
64. Buist AS. Current status of small airways disease. Chest. 1984;86:100-5.
65. Barnes PJ, Dweik RA, Gelb AF, Gibson PG, George SC, Grasemann H, et al. Exhaled nitric oxide in pulmonary diseases: a comprehensive review. Chest. 2010;138:682-92.
66. American Thoracic Society; European Respiratory Society. ATS/ERS recommendations for standardized procedures for the online and offl ine measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide. Am J Respir Crit Care Med. 2005;171:912-30.
67. Tsoukias NM, George SC. A two-compartment model of pulmonary nitric oxide exchange dynamics. J Appl Physiol. 1998;85:653-66.
68. Lehtimäki L, Kankaanranta H, Saarelainen S, Hahtola P, Järvenpää R, Koivula T, et al. Extended exhaled NO measurement differentiates between alveolar and bronchial infl ammation. Am J Respir Crit Care Med. 2001;163: 1557-61.
69. Gelb AF, George SC, Silkoff PE, Krishnan A, Fraser C, Taylor CF, et al. Central and peripheral airway/alveolar sites of exhaled nitric oxide in acute asthma. Thorax. 2010;65: 619-25.
70. Berry M, Hargadon B, Morgan A, Shelley M, Richter J, Shaw D, et al. Alveolar nitric oxide in adults with asthma: evidence of distal lung infl ammation in refractory asthma. Eur Respir J. 2005;25:986-91.
71. van Veen IH, Sterk PJ, Schot R, Gauw SA, Rabe KF, Bel EH. Alveolar nitric oxide versus measures of peripheral airway dysfunction in severe asthma. Eur Respir J. 2006; 27:951-6.
72. Gelb AF, Flynn Taylor C, Krishnan A, Fraser C, Shinar CM, Schein MJ, et al. Central and peripheral airway sites of nitric oxide gas exchange in COPD. Chest. 2010;137:575-84.
73. Van Muylem A, Kerckx Y, Michils A. Acinar effect of inhaled steroids evidenced by exhaled nitric oxide. J Allergy Clin Immunol. 2010;126:730-5.
74. Downie SR, Salome CM, Verbanck S, Thompson B, Berend N, King GG. Ventilation heterogeneity is a major determinant of airway hyperresponsiveness in asthma, independent of airway infl ammation. Thorax. 2007;62:684-9.
75. Crawford AB, Makowska M, Paiva M, Engel LA. Convection-and diffusion-dependent ventilation maldistribution in normal subjects. J Appl Physiol. 1985;59:838-46.
76. Verbanck S, Schuermans D, Noppen M, Van Muylem A, Paiva M, Vincken W. Evidence of acinar airway involvement in asthma. Am J Respir Crit Care Med. 1999;159:1545-50.
77. Verbanck S, Schuermans D, Van Muylem A, Melot C, Noppen M, Vincken W, et al. Conductive and acinar lung-zone contributions to ventilation inhomogeneity in COPD. Am J Respir Crit Care Med. 1998;157:1573-7.
78. Verbanck S, Schuermans D, Paiva M, Vincken W. Nonreversible conductive airway ventilation heterogeneity in mild asthma. J Appl Physiol. 2003;94:1380-6.
79. Verbanck S, Schuermans D, Vincken W. Infl ammation and airway function in the lung periphery of patients with stable asthma. J Allergy Clin Immunol. 2010;125:611-6.
80. Verbanck S, Schuermans D, Paiva M, Meysman M, Vincken W. Small airway function improvement after smoking cessation in smokers without airway obstruction. Am J Respir Crit Care Med. 2006;174:853-7.
81. Goldman MD, Saadeh C, Ross D. Clinical applications of forced oscillation to assess peripheral airway function. Respir Physiol Neurobiol. 2005;148:179-94.
82. Van Noord JA, Smeets J, Clément J, Van de Woestijne KP, Demedts M. Assessment of reversibility of airfl ow obstruction. Am J Respir Crit Care Med. 1994;150:551-4.
83. Paredi P, Goldman M, Alamen A, Ausin P, Usmani OS, Pride NB, et al. Comparison of inspiratory and expiratory resistance and reactance in patients with asthma and chronic obstructive pulmonary disease. Thorax. 2010;65:263-7.
84. Muskulus M, Slats AM, Sterk PJ, Verduyn-Lunel S. Fluctuations and determinism of respiratory impedance in asthma and chronic obstructive pulmonary disease. J Appl Physiol. 2010;109:1582-91.
85. Melchor R, Biddiscombe MF, Mak VH, Short MD, Spiro SG. Lung deposition patterns of directly labelled salbutamol in normal subjects and in patients with reversible airfl ow obstruction. Thorax. 1993;48:506-11.
86. Pritchard JN. The infl uence of lung deposition on clinical response. J Aerosol Med. 2001;14:S19-26.
87. Global Initiative for Asthma (GINA). 2008. Available at: http://www.ginasthma.org/(accessed 13 December 2010).
88. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007;176:532-55.
89. Gelb AF, Taylor CF, Nussbaum E, Guitierrez C, Schein A, Shinar CM, et al. Alveolar and airway sites of nitric oxide infl ammation in treated asthma. Am J Respir Crit Care Med. 2004;170:737-41.
90. Gelb AF, Taylor CF, Shinar CM, Gutierrez CA, Zamel N. Effect of fl uticasone 250 microg/salmeterol 50 microg and montelukast on exhaled nitric oxide in asthmatic patients. Can Respir J. 2008;15:193-8.
91. Fritscher LG, Rodrigues MT, Zamel N, Chapman KR. The effect of montelukast on exhaled nitric oxide of alveolar and bronchial origin in inhaled corticosteroid-treated asthma. Respir Med. 2009;103:296-300.
92. Usmani OS, Biddiscombe MF, Barnes PJ. Regional lung deposition and bronchodilator response as a function of β2-agonist particle size. Am J Respir Crit Care Med. 2005; 172:1497-504.
93. Newman S, Salmon A, Nave R, Drollmann A. High lung deposition of 99mTc-labeled ciclesonide administered via HFA-MDI to patients with asthma. Respir Med. 2006; 100:375-84.
94. Leach CL, Davidson PJ, Hasselquist BE, Boudreau RJ. Lung deposition of hydrofl uoroalkane-134a beclomethasone is greater than that of chlorofl uorocarbon fl uticasone and chlorofl uorocarbon beclomethasone: a cross-over study in healthy volunteers. Chest. 2002;122:510-6.
95. Busse WW, Brazinsky S, Jacobson K, Stricker W, Schmitt K, Vanden Burgt J, et al. Effi cacy response of inhaled beclomethasone dipropionate in asthma is proportional to dose and is improved by formulation with a new propellant. J Allergy Clin Immunol. 1999;104:1215-22.
96. De Backer W, Devolder A, Poli G, Acerbi D, Monno R, Herpich C, et al. Lung deposition of BDP/formoterol HFA pMDI in healthy volunteers, asthmatic, and COPD patients. J Aerosol Med Pulm Drug Deliv. 2010;23:137-48.
97. Papi A, Paggiaro PL, Nicolini G, Vignola AM, Fabbri LM. Beclomethasone/formoterol versus budesonide/formoterol combination therapy in asthma. Eur Respir J. 2007;29: 682-9.
98. Papi A, Paggiaro P, Nicolini G, Vignola AM, Fabbri LM. Beclomethasone/formoterol vs fl uticasone/salmeterol inhaled combination in moderate to severe asthma. Allergy. 2007; 62:1182-8.
99. Yamaguchi M, Niimi A, Ueda T, Takemura M, Matsuoka H, Jinnai M, et al. Effect of inhaled corticosteroids on small airways in asthma: investigation using impulse oscillometry. Pulm Pharmacol Ther. 2009;22:326-32.
100. Hoshino M. Comparison of effectiveness in ciclesonide and fl uticasone propionate on small airway function in mild asthma. Allergol Int. 2010;59:59-66.
101. Verbanck S, Schuermans D, Paiva M, Vincken W. The functional benefi t of anti-infl ammatory aerosols in the lung periphery. J Allergy Clin Immunol. 2006;118:340-6.
102. Cohen J, Douma WR, ten Hacken NH, Vonk JM, Oudkerk M, Postma D. Ciclesonide improves measures of small airway involvement in asthma. Eur Respir J. 2008;31: 1213-20.
103. Lehtimä k i L, Kankaanranta H, Saarelainen S, Turjanmaa V, Moilanen E. Inhaled fl uticasone decreases bronchial but not alveolar nitric oxide output in asthma. Eur Respir J. 2001;18: 635-9.
104. Zierenberg B. Optimizing the in vitro performance of Respimat. J Aerosol Med. 1999;1:S19-24.
105. Newman SP, Brown J, Steed SP, Reader SJ, Kladders H. Lung deposition of fenoterol and fl unisolide delivered using a novel device for inhaled medicines. Chest. 1998;113:957-63.
106. Pitcairn G, Reader R, Pavia D, Newman S. Deposition of corticosteroid aerosol in the human lung by Respimat ® Soft Mist ™ Inhaler compared to deposition by metered dose inhaler or by Turbuhaler ® dry powder inhaler. J Aerosol Med. 2005;18:264-72.
107. Brand P, Hederer B, Austen G, Dewberry H, Meyer T. Higher lung deposition with Respimat Soft Mist inhaler than HFA-MDI in COPD patients with poor technique. Int J Chron Obstruct Pulmon Dis. 2008;3:763-70.
108. Brand P, Meyer T, Weuthen T, Timmer W, Berkel E, Wallenstein G, et al. Lung deposition of radiolabeled tiotropium in healthy subjects and patients with chronic obstructive pulmonary disease. J Clin Pharmacol. 2007;47:1335-41.
109. Ichinose M, Fujimoto T, Fukuchi Y. Tiotropium 5microg via Respimat and 18microg via HandiHaler; effi cacy and safety in Japanese COPD patients. Respir Med. 2010;104: 228-36.
110. Michele TM, Pinheiro S, Iyasu S. The safety of tiotropium-the FDA ' s conclusions. N Engl J Med. 2010;363:1097-9.
111. Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359:1543-54.